Company type | Public |
---|---|
Industry | Pharmaceutical |
Founded | 2000 |
Defunct | 2016 |
Successor | Relief Therapeutics |
Headquarters | Stans, Switzerland |
Mondobiotech was a Swiss-based biotechnology company focused on developing human peptides as medicaments for patients affected by rare diseases.
History
Mondobiotech was founded in 2000 by Fabio Cavalli and Dorian Bevec. The company listed on the Zurich exchange in 2009. In March 2012, Pharma Times in exclusive negotiations with Pierrel Research, the contact research division of the Italian company Pierrel.
Research and development
Mondobiotech created drugs for rare diseases.
Achievements
- Winner of the Swiss Life Sciences Prize 2005.
- Selected Technology Pioneer 2008 by The World Economic Forum.
Notes and references
- "Mondobiotech". Archived from the original on 2012-07-20. Retrieved 2012-02-29.
- "Swiss Mondobiotech to list on Zurich exchange". Reuters. August 26, 2009. Retrieved November 5, 2021.
- Mansell, Peter (6 March 2012). "Pierrel in negotiations for mondoBIOTECH merger". Pharma Times. Retrieved 9 March 2015.
See also